Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Academic Article uri icon

Overview

abstract

  • STUDY DESIGN: Nineteen dogs underwent L4-L5 intertransverse process fusions with either 58 micrograms, 115 micrograms, 230 micrograms, 460 micrograms, or 920 micrograms of recombinant human bone morphogenetic protein-2 carried by a polylactic acid polymer. A previous study (12 dogs) compared 2300 micrograms of recombinant human bone morphogenetic protein-2, autogenous iliac bone, and carrier alone in this model. All fusions subsequently were compared. OBJECTIVES: To characterize the dose-response relationship of recombinant human bone morphogenetic protein-2 in a spinal fusion model. SUMMARY OF BACKGROUND DATA: Recombinant osteoinductive morphogens, such as recombinant human bone morphogenetic protein-2, are effective in vertebrate diaphyseal defect and spinal fusion models. It is hypothesized that the quality of spinal fusion produced with recombinant human bone morphogenetic protein-2, above a threshold dose, does not change with increasing amounts of inductive protein. METHODS: After decortication of the posterior elements, the designated implants were placed along the intertransverse process space bilaterally. The fusion sites were evaluated after 3 months by computed tomography imaging, high-resolution radiography, manual testing, mechanical testing, and histologic analysis. RESULTS: As in the study using 2300 micrograms of recombinant human bone morphogenetic protein-2, implantation of 58-920 micrograms of recombinant human bone morphogenetic protein-2 successfully resulted in intertransverse process fusion in the dog by 3 months. This had not occurred in animals containing autograft or carrier alone. The cross-sectional area of the fusion mass and mechanical stiffness of the L4-L5 intersegment were not dose-dependent. Histologic findings varied but were not related to rhBMP-2 dose. Inflammatory reaction to the composite implant was proportional inversely to the volume of the fusion mass. CONCLUSIONS: No mechanical, radiographic, or histologic differences in the quality of intertransverse process fusion resulted from a 40-fold variation in dose of recombinant human bone morphogenetic protein-2.

publication date

  • September 15, 1996

Research

keywords

  • Bone Morphogenetic Proteins
  • Lumbar Vertebrae
  • Recombinant Proteins
  • Spinal Fusion
  • Transforming Growth Factor beta

Identity

Scopus Document Identifier

  • 0029740478

Digital Object Identifier (DOI)

  • 10.1097/00007632-199609150-00012

PubMed ID

  • 8893436

Additional Document Info

volume

  • 21

issue

  • 18